Australian Prescriber最新文献

Pharmacovigilance in Australia: how do adverse event reports from clinicians contribute to medicine and vaccine safety? 澳大利亚的药物警戒：临床医生的不良事件报告如何促进药物和疫苗安全？

IF 3.4

Australian Prescriber Pub Date : 2024-12-01 DOI: 10.18773/austprescr.2024.056

Deborah Greenbaum, Stephanie Cheung, Claire Turner, Fiona Mackinnon, Claire Larter

{"title":"Pharmacovigilance in Australia: how do adverse event reports from clinicians contribute to medicine and vaccine safety?","authors":"Deborah Greenbaum, Stephanie Cheung, Claire Turner, Fiona Mackinnon, Claire Larter","doi":"10.18773/austprescr.2024.056","DOIUrl":"https://doi.org/10.18773/austprescr.2024.056","url":null,"abstract":"Reporting adverse events (adverse drug reactions) associated with medicines and vaccines assists with identifying previously unrecognised side effects and other safety concerns. Reporting adverse events to the Therapeutic Goods Administration is mandatory for sponsors (pharmaceutical companies), and strongly encouraged but voluntary for healthcare professionals and consumers. Adverse events should be reported even when causality is uncertain, as reports may contribute to identification of a safety signal for new or uncommon events. Suspected adverse events associated with new medicines and vaccines (registered in the last 5 years), and medicines included in the Black Triangle Scheme, should be prioritised for reporting. For other medicines, serious adverse events and unexpected adverse events should be prioritised. The Therapeutic Goods Administration analyses adverse event reporting data and uses signal detection methods to identify and evaluate emerging safety signals, which may lead to regulatory actions and communication to address safety issues.","PeriodicalId":55588,"journal":{"name":"Australian Prescriber","volume":"47 6","pages":"186-191"},"PeriodicalIF":3.4,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11703569/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142959394","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Therapeutic vapes for smoking cessation and nicotine dependence. 戒烟和尼古丁依赖的治疗性电子烟。

IF 3.4

Australian Prescriber Pub Date : 2024-12-01 DOI: 10.18773/austprescr.2024.054

Eileen Cole, Catherine Segan, Sacha Filia, Jennifer Kyi, Donita Baird

{"title":"Therapeutic vapes for smoking cessation and nicotine dependence.","authors":"Eileen Cole, Catherine Segan, Sacha Filia, Jennifer Kyi, Donita Baird","doi":"10.18773/austprescr.2024.054","DOIUrl":"https://doi.org/10.18773/austprescr.2024.054","url":null,"abstract":"The Australian Government has enacted laws restricting the supply of electronic cigarettes (vapes) to people requiring them for smoking cessation or the treatment of nicotine dependence, under the care of a medical practitioner, nurse practitioner or pharmacist. Currently no vapes are included on the Australian Register of Therapeutic Goods, meaning that the prescription and supply of therapeutic vapes must be through the Special Access Scheme or Authorised Prescriber pathways. Clinical guidelines state that therapeutic vapes may be considered for supporting people who have been unable to quit smoking using first-line therapies (a combination of behavioural support and registered nicotine replacement therapies or oral smoking cessation medicines). Clinical review should occur 1 week after vape initiation, with additional follow-up according to an individualised management plan, to monitor progress, review adverse effects (e.g. cough, irritated throat, headache or nausea), encourage the use of behavioural smoking cessation supports, and discourage dual use of vapes and conventional cigarettes. An attempt to wean or stop vaping after 12 weeks is recommended, with a possible transition to registered smoking cessation medicines if required (in addition to ongoing behavioural support). The maximum recommended duration of vape use is 12 months.","PeriodicalId":55588,"journal":{"name":"Australian Prescriber","volume":"47 6","pages":"171-176"},"PeriodicalIF":3.4,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11703573/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142959408","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Establishing a national standard to achieve better outcomes for people living with chronic obstructive pulmonary disease. 建立国家标准，以改善慢性阻塞性肺病患者的预后。

IF 3.4

Australian Prescriber Pub Date : 2024-12-01 DOI: 10.18773/austprescr.2024.053

Lee Fong, Maria B Sukkar, Rana Ahmed, Alice Bhasale

引用次数: 0

Acute tacrolimus toxicity due to concomitant use of ritonavir (with nirmatrelvir as Paxlovid). 急性他克莫司毒性由于同时使用利托那韦（与尼马特利韦作为Paxlovid）。

IF 3.4

Australian Prescriber Pub Date : 2024-12-01 DOI: 10.18773/austprescr.2024.052

Evan Browne, Cameron White, David Darley, Bridin Murnion

引用次数: 0

Top 10 drugs 2023-24. 2023- 2024年十大药物。